DBV Technologies (DBVT) Stock: Buy, Sell, or Hold?
DBVT - DBV Technologies S.A.
$11.21
-0.55 (-4.68%)
▼
5d:
-3.36%
30d:
-16.47%
90d:
-29.14%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Oct 27, 2026
24d
Get Alerted When DBVT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: DBVT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: DBVT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: DBVT is currently trading at $11.21, which is considered oversold relative to its 30-day fair value range of $11.75 to $13.83.
Technical Outlook: Technically, DBVT is in a strong downtrend. The price is currently testing key support at $11.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $38.88 (+246.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DBVT is in a strong downtrend. The price is currently testing key support at $11.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $38.88 (+246.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.75 -
$13.83
Company Quality Score
43/100
(HOLD)
Options IV Signal
7th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 7th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 246.9% below Wall St target ($38.88)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.75 -
$13.83
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.06
(9.4%)
Support & Resistance Levels
Support Level
$11.02
Resistance Level
$12.73
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.83
Wall Street Target
$38.88
(+246.9%)
Revenue Growth (YoY)
-53.3%
Share & Embed Analysis
Last updated: October 02, 2026 6:05 AM ET
Data refreshes hourly during market hours. Next update: 7:05 AM
Data refreshes hourly during market hours. Next update: 7:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DBVT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |